Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NET-CD38 Study
2024-512164-63-00Phase 2Authorised
- Sponsor
- Hospices Civils de Lyon
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of daratumumab in toxic epidermal necrolysis (TEN), sponsored by Hospices Civils de Lyon. Primary endpoints: Tolerance of daratumumab in active toxic epidermal necrolysis and Efficacy of daratumumab in active toxic epidermal necrolysis. Planned start Apr 2025; status: authorised.
02
Drugs
daratumumab
03
Conditions
toxic epidermal necrolysis (TEN)
Beyond the preview
Go deeper on 2024-512164-63-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512164-63-00.